Medication info
Exmet XR Tablets 50/500 mg

Exmet XR Tablets 50/500 mg

Prescription medicationTabletOral
Ingredient · strength
Sitagliptin Hydrochloride Hydrate›56.7mg / 1 tabletMetformin Hydrochloride›500mg / 1 tablet
Manufacturer / importer
Genewon Science Co., Ltd.
Appearance
Light blue, oval, biconvex extended-release film-coated tablet
Packaging
28 tablets/bottle, 200 tablets/bottle, 56 tablets/bottle
Approval status
Active

MFDS item code 202202076 · Approved 2022.05.17 · Insurance code 671707160

Summary

Main use
Improvement of glycemic control in patients with type 2 diabetes mellitus
Who takes it
Adults
Adult dose
For antidiabetic therapy, the dose of this medicine should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: sitagliptin 100 mg and metformin 2000 mg. To reduce gastrointestinal adverse reactions caused by metformin, take this medicine with meals once daily, preferably in the evening, and increase the dose gradually. To maintain its extended-release properties, swallow this medicine whole; do not split, crush, grind, or chew it. Take one 100/1000 mg extended-release tablet once daily. Patients taking the 50/500 mg or 50/1000 mg extended-release tablets should take 2 tablets together once daily. 1. Patients not currently receiving metformin: For patients who have not previously received drug therapy for diabetes and whose blood glucose is not adequately controlled with monotherapy, or whose blood glucose cannot be adequately controlled with sitagliptin monotherapy, the initial total daily dose of this medicine is sitagliptin 100 mg and metformin 1000 mg. If adequate blood glucose control is not achieved with the initial dose, the dose may be increased gradually up to the maximum recommended daily dose of metformin, 2000 mg, to reduce gastrointestinal adverse reactions caused by metformin. Patients with renal impairment who are receiving a reduced dose of sitagliptin should not be switched to this medicine. 2. Patients receiving metformin: - The recommended initial total daily dose of this medicine for patients whose blood glucose is not adequately controlled with metformin monotherapy is sitagliptin 100 mg plus their current dose of metformin. - Patients switching to this medicine from combination therapy with sitagliptin and metformin may start at their current doses of sitagliptin and metformin. - Patients taking immediate-release metformin at their current dose of 850 mg or 1000 mg twice daily may start with 2 tablets of this medicine, 50/1000 mg extended-release, once daily. 3. Patients whose blood glucose is not adequately controlled with combination therapy of metformin and a sulfonylurea, metformin and insulin, or metformin and a thiazolidinedione: The initial total daily dose of this medicine is sitagliptin 100 mg, and the initial dose of metformin should be determined based on the patient's blood glucose level and current dose. Increase the dose gradually to reduce gastrointestinal adverse reactions caused by metformin. When used in combination with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of sulfonylurea- or insulin-induced hypoglycemia. Patients with renal impairment This medicine may be used in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] ≥ 45 and <60 mL/min or estimated glomerular filtration rate [eGFR] ≥ 45 and <60 mL/min/1.73m2), who have no other condition that may increase the risk of lactic acidosis, with the following dose adjustment. Treatment should not be initiated with this medicine because the starting dose of metformin is 500 mg or 850 mg once daily. The maximum recommended dose of metformin is 1000 mg per day. Renal function should be monitored carefully every 3-6 months. If renal function declines to CrCl <45 mL/min or eGFR <45 mL/min/1.73m2, this medicine should be discontinued immediately. Patients with hepatic impairment This medicine should not be administered to patients with hepatic impairment because it contains metformin.

Ingredients

Manufacturer
Genewon Science Co., Ltd.

Efficacy & effects

Improvement of glycemic control in patients with type 2 diabetes mellitus

View approved original text

This medication combines sitagliptin and metformin to assist patients with type 2 diabetes in controlling their blood sugar levels. By taking this medication in addition to dietary and exercise therapies, effective management of blood sugar can be achieved. This helps maintain healthy blood sugar levels and improves symptoms of diabetes.

How to take

Adult dose

For antidiabetic therapy, the dose of this medicine should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: sitagliptin 100 mg and metformin 2000 mg. To reduce gastrointestinal adverse reactions caused by metformin, take this medicine with meals once daily, preferably in the evening, and increase the dose gradually. To maintain its extended-release properties, swallow this medicine whole; do not split, crush, grind, or chew it. Take one 100/1000 mg extended-release tablet once daily. Patients taking the 50/500 mg or 50/1000 mg extended-release tablets should take 2 tablets together once daily. 1. Patients not currently receiving metformin: For patients who have not previously received drug therapy for diabetes and whose blood glucose is not adequately controlled with monotherapy, or whose blood glucose cannot be adequately controlled with sitagliptin monotherapy, the initial total daily dose of this medicine is sitagliptin 100 mg and metformin 1000 mg. If adequate blood glucose control is not achieved with the initial dose, the dose may be increased gradually up to the maximum recommended daily dose of metformin, 2000 mg, to reduce gastrointestinal adverse reactions caused by metformin. Patients with renal impairment who are receiving a reduced dose of sitagliptin should not be switched to this medicine. 2. Patients receiving metformin: - The recommended initial total daily dose of this medicine for patients whose blood glucose is not adequately controlled with metformin monotherapy is sitagliptin 100 mg plus their current dose of metformin. - Patients switching to this medicine from combination therapy with sitagliptin and metformin may start at their current doses of sitagliptin and metformin. - Patients taking immediate-release metformin at their current dose of 850 mg or 1000 mg twice daily may start with 2 tablets of this medicine, 50/1000 mg extended-release, once daily. 3. Patients whose blood glucose is not adequately controlled with combination therapy of metformin and a sulfonylurea, metformin and insulin, or metformin and a thiazolidinedione: The initial total daily dose of this medicine is sitagliptin 100 mg, and the initial dose of metformin should be determined based on the patient's blood glucose level and current dose. Increase the dose gradually to reduce gastrointestinal adverse reactions caused by metformin. When used in combination with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of sulfonylurea- or insulin-induced hypoglycemia. Patients with renal impairment This medicine may be used in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] ≥ 45 and <60 mL/min or estimated glomerular filtration rate [eGFR] ≥ 45 and <60 mL/min/1.73m2), who have no other condition that may increase the risk of lactic acidosis, with the following dose adjustment. Treatment should not be initiated with this medicine because the starting dose of metformin is 500 mg or 850 mg once daily. The maximum recommended dose of metformin is 1000 mg per day. Renal function should be monitored carefully every 3-6 months. If renal function declines to CrCl <45 mL/min or eGFR <45 mL/min/1.73m2, this medicine should be discontinued immediately. Patients with hepatic impairment This medicine should not be administered to patients with hepatic impairment because it contains metformin.

Precautions

This medication contains sitagliptin and metformin hydrochloride, used for the treatment of type 2 diabetes. First, sitagliptin may rarely cause serious allergic reactions. If symptoms such as rash, difficulty breathing, or swelling of the face or neck occur, stop taking this medication immediately and consult a physician. Additionally, acute pancreatitis may occur during sitagliptin administration. If symptoms such as abdominal pain, vomiting, or loss of appetite appear, inform healthcare professionals immediately. Metformin hydrochloride can cause a rare but serious side effect known as lactic acidosis, which may present as muscle pain, weakness, difficulty breathing, or abdominal pain. If these symptoms occur, stop taking the medication and seek medical attention. This medication should not be administered to patients with moderately impaired kidney function or those with acute infections, dehydration, severe heart failure, or acute myocardial infarction. Also, prior to and after examinations involving iodine-based contrast agents, this medication should be discontinued for a period to avoid worsening kidney function, and it should be restarted only after confirming normal kidney function. It is safest not to use this medication in pregnant women or those who may become pregnant, as well as nursing mothers. While taking this medication, maintain regular meals and appropriate exercise, and undergo routine checks of blood sugar, kidney function, and blood tests. Symptoms of hypoglycemia such as dizziness, cold sweat, or severe fatigue may occur, especially when taken in conjunction with insulin or sulfonylureas, so caution regarding the risk of hypoglycemia is advised. Avoid excessive alcohol consumption while taking this medication, and temporarily discontinue use if oral intake is difficult due to surgery or severe infections. Finally, if any abnormal skin reactions such as blisters or severe joint pain occur while taking this medication, inform healthcare professionals immediately.

Side effects

  • Anaphylaxis
  • angioedema
  • Stevens-Johnson syndrome
  • acute pancreatitis
  • lactic acidosis
  • hypoglycemia
  • diarrhea
  • upper respiratory tract infection
  • headache
  • nausea
Show 18 more
  • vomiting
  • abdominal pain
  • nasopharyngitis
  • constipation
  • severe and disabling arthralgia
  • bullous pemphigoid
  • myalgia
  • limb pain
  • back pain
  • interstitial lung disease
  • pruritus
  • thrombocytopenia
  • rhabdomyolysis
  • elevated liver enzymes
  • rash
  • urticaria
  • cutaneous vasculitis
  • acute renal failure

Not everyone experiences these, and they can vary from person to person.

Storage

This medication is sensitive to air and moisture, so it should be stored in a closed container. It is important to maintain a storage temperature between 1 and 30 degrees Celsius to preserve the medication's effectiveness over time.

Appearance and packaging

Appearance

Light blue, oval, biconvex extended-release film-coated tablet

Package unit

28 tablets/bottle, 200 tablets/bottle, 56 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.